Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
All Genders
NCT06697938

Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study

Led by Sichuan Cancer Hospital and Research Institute · Updated on 2024-11-20

148

Participants Needed

1

Research Sites

140 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study focuses on preoperative treatment modalities for luminal-type locally advanced breast cancer. Based on modern precision radiotherapy technologies such as MRI-Linac, CyberKnife, and VMAT, it aims to compare the pCR rate, breast conserving surgery (BCS) rate, progression-free survival (PFS), and treatment-related side effects between preoperative neoadjuvant chemotherapy and preoperative neoadjuvant SBRT combined with chemotherapy in patients with this type of breast cancer. The goal is to provide new strategic options for the preoperative treatment of luminal-type locally advanced breast cancer.

CONDITIONS

Official Title

Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathologically confirmed invasive breast cancer
  • Breast MRI showing stage IIB to IIIC according to 2017 AJCC 8th edition
  • Clinical staging including chest MRI and/or axillary ultrasound, CT scans of neck, abdomen, pelvis, and bone scans
  • Karnofsky performance score of 80 or higher, or ECOG performance status of 0 to 1
  • No history of allergy to doxorubicin, cyclophosphamide, paclitaxel, or docetaxel
  • No prior treatment with radiotherapy, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy
Not Eligible

You will not qualify if you...

  • History of other malignancies except curable non-melanoma skin cancer and cervical carcinoma in situ
  • Inability to complete MRI
  • Diagnosis of inflammatory breast cancer
  • Presence of bilateral or multifocal primary tumors
  • Active infection
  • Clinically evident heart disease
  • Myocardial infarction or stroke within 6 months before enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sichuan Cancer Hospital

Chengdu, Sichuan, China, 610041

Actively Recruiting

Loading map...

Research Team

Q

Qian Peng, Phd

CONTACT

R

Rui Li, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here